If you have noticed that a sore muscle that would have recovered in two days now takes five, or that a minor injury that healed quickly at 30 lingers for weeks at 65, science now has a specific molecular explanation for why, and a surprising complexity in what fixing it might involve.
A new UCLA study found that stem cells in aged muscle accumulate higher levels of a protein called NDRG1 that slows their ability to activate and repair tissue, but helps the cells survive longer in the harsh environment of aging tissue. The research team, led by postdoctoral scholars Jengmin Kang and Daniel Benjamin and senior author Dr. Thomas Rando, discovered that NDRG1 increased dramatically with age — reaching levels 3.5 times higher in old cells than in young cells.
"It's counterintuitive, but the stem cells that make it through aging may actually be the least functional ones. They survive not because they're the best at their job, but because they're the best at surviving," said Dr. Rando, director of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA.
Why This Matters
Muscle repair capacity affects far more than athletic performance. In adults over 60, the ability to recover from muscle injury, surgical procedures, illness, and physical exertion directly correlates with functional independence, fall risk, and long-term survival.
Sarcopenia — the progressive loss of muscle mass and function with aging — affects more than 30% of Americans over 70 and is independently associated with falls, hospitalizations, cognitive decline, and early death. Understanding why aging muscles heal more slowly is the necessary first step toward developing interventions that might slow or reverse that process.
The UCLA research does not produce a treatment. But it identifies the specific molecular mechanism — and reveals an important constraint on how that mechanism might eventually be targeted.
What We Know So Far
The UCLA team, published January 29, 2026 in the journal Science, discovered that NDRG1 acts as a cellular brake, suppressing a key signaling pathway called mTOR that normally promotes cell activation and growth. To test whether NDRG1 was responsible for the slower muscle repair seen in aging, the researchers allowed mice to age normally to the equivalent of about 75 human years, then blocked NDRG1's activity. The aged muscle stem cells immediately behaved like young cells again, reactivating quickly and accelerating muscle repair after injury.
That result is significant. But so is what came next.
Without NDRG1's protective effects, fewer muscle stem cells survived over time, impairing regeneration after repeated injuries. The study revealed a trade-off, favoring stem cell persistence over regenerative speed as tissues age.
This means that NDRG1 is not simply a malfunction in aging — it appears to be an evolved protective mechanism that keeps aging muscle stem cells alive, at the expense of their repair speed. Simply eliminating NDRG1 restores fast repair in the short term but depletes the stem cell pool over time — producing a worse outcome after subsequent injuries.
The research suggests this happens through what the scientists call a "cellular survivorship bias": stem cells that don't accumulate enough NDRG1 die off over time, leaving behind a population of slower but more resilient cells.
What the Evidence Shows — and What It Does Not
This study was conducted in mice and has not been tested in human muscle tissue. The molecular mechanisms involved — NDRG1, mTOR signaling, muscle satellite cell behavior — are conserved between mice and humans, making the findings biologically relevant, but the direct translational implications have not been established.
MedicalDaily Evidence Check
- Study type : Preclinical (animal model — mice)
- Published in : Science , January 29, 2026; renewed ScienceDaily coverage June–July 2026
- Institution : UCLA Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research
- Key finding : NDRG1 accumulates 3.5× higher in aged muscle stem cells; acts as mTOR brake; blocking NDRG1 restored fast repair but reduced stem cell survival over time
- What it found : The specific molecular reason aging muscles heal more slowly, and an unexpected trade-off in the potential therapeutic target
- What it did not prove : That any intervention targeting NDRG1 is safe or effective in humans
- What readers should know : This is a foundational mechanistic discovery; no treatment is currently available based on this finding
Where the Research Fits in the Aging Biology Landscape
The mTOR pathway — which NDRG1 suppresses — is one of the most studied molecular targets in aging biology. Rapamycin, an FDA-approved immunosuppressant that inhibits mTOR, has been shown to extend lifespan in mice and is an active subject of longevity research. The UCLA finding adds a new layer: NDRG1 is an upstream regulator of mTOR in the specific context of aging muscle stem cells, and its effects cannot simply be overridden by suppressing mTOR directly without engaging the survival trade-off.
As Rando explained the trade-off: "Think of it like a marathon runner versus a sprinter. The stem cells in young animals are hyper-functioning — really good at what they do, namely sprinting, but they're not good for the long term. They can make it through the 100-yard dash, but they can't make it even halfway through the marathon. By contrast, aged stem cells are like marathon runners — slower to respond, but better equipped for the long haul. However, what makes them so proficient over long distances is exactly what renders them poor at sprinting."
Future interventions targeting this pathway may need to address both sides of the equation — restoring repair speed without depleting the stem cell population — a more complex therapeutic design challenge than the initial finding suggests.
Who Faces the Greatest Impact?
Adults most affected by age-related slowing of muscle repair include:
- Adults 60 and older recovering from surgical procedures, particularly orthopedic surgeries
- Older adults recovering from illness-related immobility, where muscle atrophy accelerates rapidly
- Individuals with pre-existing sarcopenia in whom muscle stem cell reserves are already reduced
- Post-injury athletes and active adults over 50 who notice slower-than-expected recovery timelines
What Doctors and Experts Say
Dr. Rando described the trade-off in evolutionary terms: in harsh conditions — droughts, famines, extreme cold — many animals activate resilience programs that divert energy away from reproduction and toward survival. Aging may trigger a parallel survival program in muscle stem cells, prioritizing longevity over rapid repair. "Some age-related changes that look detrimental — like slower tissue repair — may actually be necessary compromises that prevent something worse: the complete depletion of the stem cell pool," he said.
Independent exercise scientists and geriatricians have noted that the UCLA finding is consistent with clinical observations: older adults recover more slowly after the same exercise stimulus than younger adults, even when matched for fitness level and nutrition.
Symptoms and Warning Signs to Watch For
The following may indicate accelerated age-related muscle decline that warrants evaluation:
- Persistent muscle soreness beyond 5 to 7 days after moderate exercise
- Unexpected difficulty recovering from minor injuries
- Visible loss of muscle bulk in the thighs, arms, or shoulders over a 6- to 12-month period
- Increasing difficulty with activities requiring leg strength, such as rising from a chair or climbing stairs
These symptoms warrant a conversation with a primary care provider or a geriatrician about functional strength assessment.
What You Can Do Now
- Prioritize resistance training. Current evidence consistently shows that progressive resistance exercise is the most effective available intervention for maintaining muscle stem cell function and slowing sarcopenia. Both the rate and the direction of age-related muscle decline are modifiable through regular strength training.
- Maintain adequate protein intake. A minimum of 0.6 to 0.8 grams of protein per pound of body weight daily is recommended by most exercise physiologists for adults over 60, increasing to 0.8 to 1.0 grams per pound during recovery from injury.
- Optimize sleep. Growth hormone — the primary driver of muscle repair — is released predominantly during deep sleep. Prioritizing consistent, adequate sleep supports the body's natural repair cycle.
- Do not self-medicate with rapamycin based on longevity research. Rapamycin suppresses mTOR and has significant immunosuppressive side effects; it is not a safe over-the-counter aging intervention.
Cost and Access: What Patients Should Know
Sarcopenia evaluation and functional muscle assessment are covered under Medicare Part B when ordered by a physician with an appropriate clinical indication. Physical therapy for age-related muscle decline is covered by Medicare and most private insurance with physician referral. Community fitness programs for older adults — including SilverSneakers — are available at reduced or no cost for many Medicare enrollees.
What Happens Next
The UCLA team plans to continue investigating how the balance between survival and regeneration is regulated at the molecular level. Future research will likely focus on identifying whether any intervention can restore NDRG1-related repair speed without the stem cell depletion cost — a more nuanced therapeutic target than simple NDRG1 inhibition. NDRG1 may represent just the first door into a much deeper understanding of how biological aging is controlled and, perhaps one day, how it can be thoughtfully modulated without depleting the very resources the body needs to sustain itself.
The Bottom Line
UCLA researchers have identified the specific protein responsible for slower muscle healing in aging: NDRG1 acts like a molecular brake in aging muscle stem cells, slowing repair by suppressing the mTOR pathway. Blocking it in mice restored young-cell repair behavior, but depleted the stem cell pool over time. This surprising trade-off suggests that aging involves evolved survival strategies — not simply biological failure — and that future therapies will need to address both sides of the equation. No treatment based on this research is currently available, but the finding provides the most precise molecular roadmap yet for understanding and eventually addressing one of the most consequential biological changes of normal aging.
